Search research articles
Contact Us
Filters
Showing results (141-150 of 188) with videos related to
Page
of 19
Sort By:
ESMO Open
|
December 13, 2021
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
J Tabernero, L Velez, T L Trevino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 1998
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival
G Fontanini, M De Laurentiis, S Vignati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2011
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
C Gridelli, F Morgillo, A Favaretto, et al.
Cancer Treatment Reviews
|
December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development
R Stahel, J Bogaerts, F Ciardiello, et al.
British Journal of Cancer
|
May 11, 2006
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
F Ciardiello, T Troiani, F Caputo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 1996
Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits
P Tagliaferri, G Tortora, R Guarrasi, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
December 18, 2019
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression
S Napolitano, N Matrone, A L Muddassir, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Establishment of the Campania Oncology Network (Rete Oncologica Campana, ROC): a paradigm shift in oncological care and real world research in the Campania region
E Coppola, I De Santo, A Luongo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2007
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
F Cappuzzo, G Finocchiaro, E Rossi, et al.
British Journal of Cancer
|
August 6, 2014
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells
C D'Amato, R Rosa, R Marciano, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 188) with videos related to
Sort By:
Page
of 19
ESMO Open
|
December 13, 2021
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
J Tabernero, L Velez, T L Trevino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 1998
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival
G Fontanini, M De Laurentiis, S Vignati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2011
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
C Gridelli, F Morgillo, A Favaretto, et al.
Cancer Treatment Reviews
|
December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development
R Stahel, J Bogaerts, F Ciardiello, et al.
British Journal of Cancer
|
May 11, 2006
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
F Ciardiello, T Troiani, F Caputo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 1996
Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits
P Tagliaferri, G Tortora, R Guarrasi, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
December 18, 2019
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression
S Napolitano, N Matrone, A L Muddassir, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Establishment of the Campania Oncology Network (Rete Oncologica Campana, ROC): a paradigm shift in oncological care and real world research in the Campania region
E Coppola, I De Santo, A Luongo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2007
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
F Cappuzzo, G Finocchiaro, E Rossi, et al.
British Journal of Cancer
|
August 6, 2014
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells
C D'Amato, R Rosa, R Marciano, et al.
Page
of 19